Plexus Corp. (PLXS) 10-K Summary: Fiscal Year Ended September 28, 2024
Business Context and Reporting Period
Plexus Corp. is a global provider of design, manufacturing, and sustaining services for highly complex products in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The company operates 26 facilities across the Americas (AMER), Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA) with over 20,000 employees. This filing covers the fiscal year ended September 28, 2024.
Key Financial Metrics
| Metric | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Net Sales | $3,960.8 million | $4,210.3 million |
| Gross Profit | $378.5 million | $394.6 million |
| Gross Margin | 9.6% | 9.4% |
| Operating Income | $167.7 million | $195.8 million |
| Operating Margin | 4.2% | 4.7% |
| Net Income | $111.8 million | $139.1 million |
| Diluted EPS | $4.01 | $4.95 |
| Free Cash Flow | $341.3 million | $61.8 million |
| Cash and Equivalents | $347.5 million | $256.7 million |
| Total Debt & Leases | $247.3 million | $431.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5.9% year-over-year, driven by market-driven inventory corrections and weaker demand in Healthcare/Life Sciences (-17.1%) and Industrial (-2.8%) sectors. Aerospace/Defense sales increased 20.6%.
- Profitability Pressure: Operating income fell 14.4% due to lower gross profit and a $14.9 million increase in Selling, General, and Administrative (S&A) expenses. The S&A increase was largely due to $9.0 million in stock-based compensation, including $5.1 million from accelerated vesting related to executive retirements.
- Working Capital Improvement: Despite lower sales, Free Cash Flow surged to $341.3 million (up $279.5 million) primarily due to aggressive inventory reduction efforts, which improved the annualized cash cycle by 23 days.
- Debt Reduction: The company significantly reduced borrowings under its credit facility, repaying $183.0 million net during the year, bringing total debt and lease obligations down from $431.1 million to $247.3 million.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued market softness in Healthcare and Industrial sectors but notes early signs of improvement. The effective tax rate for fiscal 2025 is expected to be between 14.0% and 16.0%.
- Capital Allocation: Capital expenditures for fiscal 2025 are estimated at $120.0 million to $150.0 million, including $60.0 million for a facility expansion in Penang, Malaysia. The company completed a $50.0 million share repurchase program in 2024 and initiated a new $50.0 million program in August 2024.
- Risks: Key risks include component shortages and supply chain volatility, customer demand fluctuations, and geopolitical tensions affecting operations in China and Malaysia. The company also faces potential tax rate increases due to the expiration of a tax holiday in its APAC subsidiary and the implementation of global minimum tax rules starting in fiscal 2026.
- Restructuring: The company incurred $20.3 million in restructuring charges in 2024 related to workforce reductions and facility closures in AMER and EMEA.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of inventory reserves given the significant reduction in inventory levels and the risk of obsolescence in a slowing market.
- Customer Concentration: Confirm the stability of the top 10 customers, who accounted for 47.8% of net sales in 2024, and monitor for any disengagements.
- Tax Holiday Impact: Assess the financial impact of the APAC tax holiday expiration (December 31, 2034) and the anticipated rise in the effective tax rate due to global minimum tax regulations.
- Share Repurchase Execution: Track the execution of the new $50.0 million share repurchase program and its impact on diluted share count.
- Supply Chain Resilience: Evaluate the company's ability to manage component shortages and lead-time extensions without incurring excessive working capital costs.